Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of signing the consent form
• People who are willing and able to sign a consent form and follow the trial's procedures
• People diagnosed with certain types of large B-cell lymphoma (a blood cancer) that has come back or stopped responding to treatment, based on specific medical classifications (confirm with trial site)
• People whose lymphoma has returned 6 or more months after finishing treatment, or whose disease progressed during or within 6 months of completing treatment
• People who have already received at least one previous treatment for their lymphoma, including treatments containing two specific types of medication (an anti-CD20 antibody and an anthracycline-based therapy)
• People who have at least one measurable area of lymphoma that meets specific size requirements on scans
• People with a general health/activity level rating of 0, 1, or 2 on a standard medical scale (meaning they are able to carry out at least some daily activities)
• People whose blood, liver, and kidney test results fall within acceptable ranges, tested within 6 weeks before starting treatment
• People who are willing to avoid pregnancy during the trial and for at least 12 months after the last dose of the trial treatment
• People living with HIV, provided they are stable on HIV medication, have an adequate immune cell count, and have an undetectable level of the virus in their blood
• People with a life expectancy of at least 12 weeks
• People taking steroid (glucocorticoid) medication at the time of screening, provided the dose has been reduced to no more than 25 mg per day in the 14 days before the first dose of trial treatment

Who may not be able to join:

• People whose lymphoma has spread to the brain or spinal cord, or who have lymphoma that started in the central nervous system
• People who have previously been treated with a type of immune cell therapy called anti-CD19 CAR-T therapy
• People who have previously received a type of treatment called a bispecific anti-CD20xCD3 antibody
• People who have previously had a stem cell transplant (either using their own cells or a donor's cells)
• People with significant lung conditions, such as pulmonary fibrosis or chronic obstructive pulmonary disease (COPD), that affect their ability to be physically active
• People with significant heart conditions, including unstable chest pain, a heart attack within the past 6 months, or severe heart failure
• People who are pregnant or breastfeeding
• People who have not sufficiently recovered from a major surgery before starting the trial
• People with an ongoing serious infection currently requiring antibiotics, antifungal, or antiviral medication, or who needed intravenous antibiotics for a major infection within 2 weeks of the trial start
• People who have received a live vaccine within 30 days of starting the trial, or who expect to need one during the trial (note: standard flu shots and approved COVID-19 vaccines are generally permitted — confirm with trial site)
• People with an active hepatitis B infection (people with certain past hepatitis B markers may still be eligible if a specific blood test is negative — confirm with trial site)
• People with an active hepatitis C infection (people who test positive for hepatitis C antibodies may still be eligible if a further blood test is negative — confirm with trial site)
• People with a known active COVID-19 infection at the time of joining (specific testing requirements apply — confirm with trial site)
• People with severe chronic lung disease or another serious medical condition likely to make tolerating the trial treatment very difficult
• People with a seizure disorder requiring ongoing treatment who have had a seizure within the past two years
• People who do not have the capacity to make their own informed decisions

Important: Always verify eligibility with the trial site directly before applying.